Abstract:
BACKGROUND:To date, multiple myeloma remains an incurable malignancy due to the persistence of minimal residual disease in the bone marrow. In this setting, monoclonal antibodies against myeloma-specific cell surface antigens represent a promising therapeutic approach, which is however hampered by a lack of appropriate target structures expressed across all pathogenic myeloma cell populations. We, therefore, investigated functionally relevant immunoreceptors specifically associated with myeloma cells as well as their clonogenic precursors. DESIGN AND METHODS:Potential target proteins were identified using antibody arrays against phosphorylated immunoreceptors with lysates from myeloma cell lines. CD229 expression was confirmed in primary myeloma cells by reverse transcriptase polymerase chain reaction, western blot, fluorescence-activated cell sorting, and immunohistochemistry. Apoptosis, clonogenic growth, and sensitivity to chemotherapy were determined following short-interfering RNA-mediated downregulation of CD229. Antibody-dependent cellular and complement-dependent cytotoxicity were analyzed using a monoclonal antibody against CD229 to demonstrate the antigen's immunotherapeutic potential. RESULTS:Our screening assay identified CD229 as the most strongly over-expressed/phosphorylated immunoreceptor in myeloma cell lines. Over-expression was further demonstrated in the CD138-negative population, which has been suggested to represent myeloma precursors, as well as on primary tumor cells from myeloma patients. Accordingly, CD229 staining of patients' bone marrow samples enabled the identification of myeloma cells by flow cytometry and immunohistochemistry. Down-regulation of CD229 led to a decreased number of viable myeloma cells and clonal myeloma colonies, and enhanced the anti-tumor activity of conventional chemotherapeutics. Targeting CD229 with a monoclonal antibody resulted in complement- and cell-mediated lysis of myeloma cells. CONCLUSIONS:Our results demonstrate that the immunoreceptor CD229 is specifically over-expressed on myeloma cells including their clonogenic precursors and contributes to their malignant phenotype. Monoclonal antibodies against this protein may represent a promising diagnostic and immunotherapeutic instrument in this disease.
journal_name
Haematologicajournal_title
Haematologicaauthors
Atanackovic D,Panse J,Hildebrandt Y,Jadczak A,Kobold S,Cao Y,Templin J,Meyer S,Reinhard H,Bartels K,Lajmi N,Zander AR,Marx AH,Bokemeyer C,Kröger Ndoi
10.3324/haematol.2010.036814subject
Has Abstractpub_date
2011-10-01 00:00:00pages
1512-20issue
10eissn
0390-6078issn
1592-8721pii
haematol.2010.036814journal_volume
96pub_type
杂志文章相关文献
HAEMATOLOGICA文献大全abstract::The National Institutes of Health global score for chronic graft-versus-host disease was devised by experts but was not based on empirical data. We hypothesized that analysis of prospectively collected data would enable derivation of a more accurate model for estimating mortality risk. We analyzed 574 adult patients w...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究
doi:10.3324/haematol.2014.109611
更新日期:2014-10-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:We tested the principle of local International Normalized Ratio (INR) calibration using INR calibrator plasmas (PT Calibration Plasma Kit, Behring), two thomboplastin reagents (Neoplastin plus, rabbit brain, Stago, and Recombiplastin, recombinant human tissue factor, Ortho Diagnostics) and the...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2002-12-01 00:00:00
abstract::Multipotent stromal cells have immunomodulatory capacities and have been used in transplantation and autoimmune diseases. One of the effects of multipotent stromal cells involves the inhibition of dendritic cell differentiation. Since interleukin-6 and interleukin-10 are known to play a role in inhibiting immature den...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2012.078055
更新日期:2013-06-01 00:00:00
abstract:BACKGROUND:Protein S, which circulates in plasma in both free and bound forms, is an anticoagulant protein that stimulates activated protein C and tissue factor pathway inhibitor. Hereditary type I protein S deficiency (low total and low free protein S) is a well-established risk factor for venous thrombosis, whereas t...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2010.021923
更新日期:2010-09-01 00:00:00
abstract::BACKGROUND. Hypofibrinogenemia and increased fibrin(ogen) degradation products in acute leukemia have been attributed to intravascular thrombin generation triggered by leukemic cells. However, the strict relationship between fibrinogen catabolism and turnover of fibrinopeptide A (FPA), which is a sensitive and specifi...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1993-11-01 00:00:00
abstract:BACKGROUND:Allogeneic stem cell transplantation is a potentially curative treatment for myelofibrosis, although its use is limited by a high rate of transplant-related mortality. In this study, we evaluated the outcome of patients with myelofibrosis who underwent allogeneic stem cell transplantation, and the impact of ...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.12828
更新日期:2008-10-01 00:00:00
abstract::Recent studies indicate that a subset of patients with apparently acquired aplastic anemia (AA) have mutations in genes for telomerase ribonucleoprotein complex components. We looked for mutations in telomerase RNA (TERC) and telomerase reverse transcriptase (TERT) in 96 Japanese children with acquired AA and in 76 he...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2006-05-01 00:00:00
abstract::We conducted a phase I/II multicenter trial using 6 cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive (+) B-cell lymphomas. Thirty-one patients were evaluable for toxicity and 29 for efficacy including 22...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2019.238675
更新日期:2020-05-15 00:00:00
abstract:BACKGROUND AND OBJECTIVE:The threshold for prophylactic platelet transfusions has been classically established at 20,000/microL. In 48 patients with de novo acute myeloblastic leukemia (AML) we analyzed the effect of reducing the threshold for prophylactic platelet transfusion from 20,000/microL (group A) to 10,000/mic...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1998-11-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in patients affected by hereditary bleeding disorders and treated with non-virus inactivated clotting factor concentrates during the 1970s. INFORMATION SOURCES:In this review, we briefly report the present know...
journal_title:Haematologica
pub_type: 杂志文章,评审
doi:
更新日期:2002-05-01 00:00:00
abstract::Post-transfusion hepatitis (PTH) is a major problem in patients with acute leukemias requiring blood products during induction or consolidation therapy. In fact, PTH causes delays of chemotherapy with major violations in the timing of protocols. In order to assess the efficacy and safety of a short course of alpha-int...
journal_title:Haematologica
pub_type: 临床试验,杂志文章
doi:
更新日期:1991-09-01 00:00:00
abstract::The risk of developing premature ovarian failure and azoospermia is a major concern in long-term survivors treated for Hodgkin's lymphoma. Alkylating chemotherapy containing procarbazine and/or cyclophosphamide causes prolonged azoospermia in 90-100% of men and premature ovarian failure in 5-25% of women under the age...
journal_title:Haematologica
pub_type: 杂志文章,评审
doi:10.3324/haematol.2011.045856
更新日期:2011-11-01 00:00:00
abstract::High levels of HbF were found in patients with myelodysplastic syndrome (MDS), as well as a possible switching of the ratio of the gamma chains from the adult to the newborn type in 25% of our patients. These abnormalities in general were not present in the parents. The possibility of having thalassemia or other hemog...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:1991-07-01 00:00:00
abstract::The prognosis of patients with acute myeloid leukemia in whom primary treatment fails remains very poor. In order to improve such patients' outcome, we conducted a phase 2, prospective, multicenter trial to test the feasibility of a new sequential regimen, combining a short course of intensive chemotherapy and a reduc...
journal_title:Haematologica
pub_type: 杂志文章,多中心研究
doi:10.3324/haematol.2016.150326
更新日期:2017-01-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Autologous stem cell transplantation (ASCT) is currently being evaluated as a therapy for patients with multiple sclerosis (MS). We report the results of a phase II trial to evaluate feasibility and toxicity of CD34+ selected ASCT (CD34+/ASCT) and treatment results at one year of follow-up. D...
journal_title:Haematologica
pub_type: 临床试验,杂志文章
doi:
更新日期:2003-03-01 00:00:00
abstract:BACKGROUND AND OBJECTIVE:Altered adhesive interaction between bone marrow (BM) stroma and progenitors in chronic myeloid leukemia (CML) may be in part caused by abnormal expression of cell adhesion molecules (CAMs) on malignant progenitor cells. Treatment of CML with interferon-a (IFN-a) re-establishes normal hemopoies...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2000-02-01 00:00:00
abstract::Myeloproliferative neoplasms are a varied group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform into a secondary acute myeloid leukemia that is ultimately fatal. Triapine is a novel inhibitor of the M2 subunit of ribonucleotide reductase. Sequential inhibition of ribonu...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2013.097246
更新日期:2014-04-01 00:00:00
abstract:UNLABELLED:BACKGROUND Very severe aplastic anemia is characterized by a hypoplastic bone marrow due to destruction of CD34(+) stem cells by autoreactive T cells. Investigation of the pathomechanism by patient-specific gene expression analysis of the attacked stem cells has previously been impractical because of the sca...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2011.056705
更新日期:2012-09-01 00:00:00
abstract::New drugs are needed for the treatment of relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown that this drug has excellent activity in those leukemias with RAS pathway mutations. The proapoptotic protein, BIM is pivotal in the induction of cell death by both se...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2017.185975
更新日期:2019-09-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:Patients with chronic renal failure show signs of accelerated atherosclerosis and high cardiovascular morbidity and mortality. Recent investigations indicate that uremia is associated with endothelial dysfunction and a microinflammatory state. We assessed changes in the expression of adhesion ...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2002-10-01 00:00:00
abstract::Pathological erythropoiesis with consequent anemia is a leading cause of symptomatic morbidity in internal medicine. The etiologies of anemia are complex and include reactive as well as neoplastic conditions. Clonal expansion of erythroid cells in the bone marrow may result in peripheral erythrocytosis and polycythemi...
journal_title:Haematologica
pub_type: 杂志文章,评审
doi:10.3324/haematol.2018.192518
更新日期:2018-10-01 00:00:00
abstract:BACKGROUND:Resistance to imatinib is an important clinical issue in the treatment of Philadelphia chromosome-positive leukemias which is being tackled by the development of new, more potent drugs, such as the dual Src/Abl tyrosine kinase inhibitors dasatinib and bosutinib and the imatinib analog nilotinib. In the curre...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.12212
更新日期:2008-05-01 00:00:00
abstract::Shwachman-Diamond syndrome is a congenital bone marrow failure disorder characterized by debilitating neutropenia. The disease is associated with loss-of-function mutations in the SBDS gene, implicated in ribosome biogenesis, but the cellular and molecular events driving cell specific phenotypes in ribosomopathies rem...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2015.131573
更新日期:2015-10-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:The role of hematopoietic chimerism after allogeneic stem cell transplantation (SCT) for acute leukemia remains controversial. We studied the relationship between hematopoietic chimerism and several prognostic variables on the outcome of SCT in patients with acute leukemia. DESIGN AND METHODS...
journal_title:Haematologica
pub_type: 杂志文章
doi:
更新日期:2003-07-01 00:00:00
abstract::Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumor patients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few immune alterations are described in humans. We retrospectively stud...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.12642
更新日期:2008-08-01 00:00:00
abstract:BACKGROUND:Persistent mixed chimerism represents a state in which recipient and donor cells stably co-exist after hematopoietic stem cell transplantation. However, since in most of the studies reported in literature the engraftment state was observed in the nucleated cells, in this study we determined the donor origin ...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2010.031013
更新日期:2011-01-01 00:00:00
abstract::Distinct expression patterns of pro- and anti-apoptotic proteins may contribute to different prognoses and therapy outcomes in adult versus childhood acute myeloid leukemia (AML). Therefore, we investigated whether expression levels of apoptosis-related proteins CD95, Bcl-2, Bax, Bcl-xL, procaspase-3, XIAP, cIAP-1, an...
journal_title:Haematologica
pub_type: 信件
doi:
更新日期:2004-03-01 00:00:00
abstract::In a case of acute myeloid leukemia we report molecular cytogenetic findings of a t(3;11)(q12;p15), characterized as a new NUP98 translocation rearranging with LOC348801 at chromosome 3. NUP98 involvement was detected by fluorescence in situ hybridization. 3'-RACE-PCR showed nucleotide 1718 (exon 13) of NUP98 was fuse...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.12945
更新日期:2008-09-01 00:00:00
abstract::The role of reduced intensity allogeneic stem cell transplantation for the treatment of relapsed/refractory Hodgkin's lymphoma remains controversial. We retrospectively analyzed 191 patients who underwent reduced intensity allogeneic stem cell transplantation between 1998 and 2008 for relapsed or refractory Hodgkin's ...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2012.080895
更新日期:2013-09-01 00:00:00
abstract:BACKGROUND:LMO2 is highly expressed at the most immature stages of lymphopoiesis. In T-lymphocytes, aberrant LMO2 expression beyond those stages leads to T-cell acute lymphoblastic leukemia, while in B cells LMO2 is also expressed in germinal center lymphocytes and diffuse large B-cell lymphomas, where it predicts bett...
journal_title:Haematologica
pub_type: 杂志文章
doi:10.3324/haematol.2011.040568
更新日期:2011-07-01 00:00:00